Ottobock, the global MedTech champion and international market leader in Human Bionics, continued its growth trajectory in the first half of 2025. The company recorded a 5.0% increase in revenue to EUR 801 million in the first six months of the year (H1 2024: EUR 763 million), with organic growth of 10.0%. Strategic product launches and seven successful acquisitions significantly contributed to this positive development. At the same time, underlying EBITDA increased by 30.5% to EUR 180 million (H1 2024: EUR 138 million). This was mainly due to a favorable product mix, economies of scale, and operational efficiency improvements. Underlying EBITDA margin increased by 4.4 percentage points to 22.5% (H1 2024: 18.1%) compared to the previous year. Free cash flow rose to EUR 93 million in the first half of the year (H1: EUR 36 million), nearly triplingcompared to the same period last year. The strong capital structure enhances the company’s ability to continue investing in innovation and growth in the future. 
 
Oliver Jakobi, CEO of Ottobock SE & Co. KGaA: “Our success in the first half of 2025 once again underlines that Ottobock is on a growth path, based on our innovation strength. We continue to invest in future technologies – from intelligent prosthetics and neurotechnological interfaces to exoskeletons. Our innovation pipeline is well filled, and, together with leading research partners, we are developing solutions that are redefining our market. Innovation will remain our key growth driver.” 

Dr. Arne Kreitz, CFO of Ottobock SE & Co. KGaA: “Ottobock is thriving and in excellent financial health. We have continued the dynamic, innovation-driven growth of recent years with significant increases in revenue and margin. This makes us very confident for the second half of the year and thus also for achieving our full-year targets.” 

In the first half of 2025, Ottobock launched four strategic key products – including the new Speedhand Solution in prosthetics, the next generation of the Exopulse Suit, and the active exoskeleton Volton. A strong R&D ratio in the product and component business, as well as strategic investments in start-ups like Phantom Neuro, BionicSkins, and Musclemetrix LLC, further supports innovation and the development of pioneering technologies. The field of human-machine interfaces, as a basis for the neural control of prostheses and orthoses, is also gaining importance.